ES2654623T3 - Inhibidores bivalentes de proteínas IAP y métodos terapéuticos que los usan - Google Patents

Inhibidores bivalentes de proteínas IAP y métodos terapéuticos que los usan Download PDF

Info

Publication number
ES2654623T3
ES2654623T3 ES13831176.6T ES13831176T ES2654623T3 ES 2654623 T3 ES2654623 T3 ES 2654623T3 ES 13831176 T ES13831176 T ES 13831176T ES 2654623 T3 ES2654623 T3 ES 2654623T3
Authority
ES
Spain
Prior art keywords
hours
protein
structures
formula
separation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13831176.6T
Other languages
English (en)
Spanish (es)
Inventor
Shaomeng Wang
Rong SHENG
Haiying Sun
Liu Liu
Jianfeng Lu
Donna Mceachern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan (System)
Original Assignee
University of Michigan (System)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan (System) filed Critical University of Michigan (System)
Application granted granted Critical
Publication of ES2654623T3 publication Critical patent/ES2654623T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
ES13831176.6T 2012-08-23 2013-08-16 Inhibidores bivalentes de proteínas IAP y métodos terapéuticos que los usan Active ES2654623T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261692429P 2012-08-23 2012-08-23
US201261692429P 2012-08-23
PCT/US2013/055384 WO2014031487A1 (en) 2012-08-23 2013-08-16 Bivalent inhibitors of iap proteins and therapeutic methods using the same

Publications (1)

Publication Number Publication Date
ES2654623T3 true ES2654623T3 (es) 2018-02-14

Family

ID=50148520

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13831176.6T Active ES2654623T3 (es) 2012-08-23 2013-08-16 Inhibidores bivalentes de proteínas IAP y métodos terapéuticos que los usan

Country Status (12)

Country Link
US (1) US8883771B2 (enExample)
EP (1) EP2888265B1 (enExample)
JP (1) JP6247298B2 (enExample)
KR (2) KR102111704B1 (enExample)
CN (3) CN109575049B (enExample)
AU (1) AU2013306087B2 (enExample)
CA (1) CA2882496C (enExample)
ES (1) ES2654623T3 (enExample)
HK (1) HK1211030A1 (enExample)
MX (1) MX366130B (enExample)
RU (1) RU2649975C2 (enExample)
WO (1) WO2014031487A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
JP2017511348A (ja) * 2014-04-16 2017-04-20 成都大学 Ｂｃｒ−Ａｂｌ二倍体の阻害剤、その調製方法及びその用途
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
GB201506871D0 (en) * 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2017253560B2 (en) 2016-04-20 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
JP6953435B2 (ja) * 2016-05-09 2021-10-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二量体化合物
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
GB2567126A (en) * 2017-06-23 2019-04-10 Femtogenix Ltd PBC compounds
CN107987083A (zh) * 2017-11-24 2018-05-04 江苏亚盛医药开发有限公司 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物
BR112021000538A2 (pt) 2018-07-13 2021-04-06 F. Hoffmann-La Roche Ag Oligonucleotídeos para modular a expressão de rtel1
CA3101835A1 (en) 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
JP2022511437A (ja) 2018-11-26 2022-01-31 デバイオファーム インターナショナル エス．エー． Ｈｉｖ感染の組み合わせ治療
US10870663B2 (en) 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
US12636370B2 (en) 2019-08-08 2026-05-26 Institute For Cancer Research Combination therapy for treatment of cancer
AU2020356356A1 (en) 2019-09-25 2022-05-12 Debiopharm International S.A. Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
US12678509B2 (en) * 2019-11-08 2026-07-14 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (IAP) protein antagonists
WO2021098771A1 (en) * 2019-11-19 2021-05-27 Ascentage Pharma (Suzhou) Co., Ltd. Treatment method with iap inhibitor
CN112972684B (zh) * 2019-12-02 2024-05-31 苏州亚盛药业有限公司 Iap抑制剂与parp或mek抑制剂或其他化学治疗剂的组合
CN118542872A (zh) * 2019-12-04 2024-08-27 苏州亚盛药业有限公司 药物组合及其用途
EP4081217A1 (en) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
WO2021223664A1 (en) * 2020-05-04 2021-11-11 Ascentage Pharma (Suzhou) Co., Ltd. Methods for treating coronavirus infections
TWI794895B (zh) * 2020-07-16 2023-03-01 大陸商蘇州亞盛藥業有限公司 雙二氮雜雙環化合物或其鹽的結晶形式或無定形形式
CN116963732A (zh) * 2021-02-23 2023-10-27 苏州亚盛药业有限公司 药物组合物及其制备方法
JP2024528174A (ja) 2021-08-02 2024-07-26 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド 医薬組合せおよびその使用
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
EP4529455A1 (en) 2022-05-23 2025-04-02 Inhibrx Biosciences, Inc. Dr5 agonist and iap antagonist combination therapy
US12508320B2 (en) 2023-06-29 2025-12-30 SeeCure Taiwan Co., Ltd. Drug conjugate, pharmaceutical composition and method of treating hepatitis
AU2024367811A1 (en) * 2023-10-24 2026-05-07 Tract Pharmaceuticals, Inc. Combination of iap inhibitors and cellular kinase inhibitors, such as ponatinib, for use in the treatment of cancer or pulmonary diseases, such as copd, cystic fibrosis, pulmonary fibrosis and covid-19
WO2025261398A1 (en) * 2024-06-19 2025-12-26 Ascentage Pharma (Suzhou) Co., Ltd. Methods for treating diseases caused by hiv infection
CN119100970B (zh) * 2024-08-30 2025-09-30 中国药科大学 基于热休克蛋白90的二价抑制剂及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072831A1 (en) * 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
EP1723122B1 (en) 2004-03-01 2014-11-19 Board of Regents, The University of Texas System Dimeric small molecule potentiators of apoptosis
CN101128425B (zh) * 2005-02-25 2012-12-26 泰特拉洛吉克药业公司 Iap二聚体抑制剂
ES2525585T3 (es) * 2006-05-05 2014-12-26 The Regents Of The University Of Michigan Intermedios para la preparación de miméticos de SMAC bivalentes
WO2008128171A2 (en) * 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
ES2643233T3 (es) * 2009-10-23 2017-11-21 The Regents Of The University Of Michigan Miméticos de SMAC bicíclicos diazo bivalentes y los usos de los mismos

Also Published As

Publication number Publication date
AU2013306087A1 (en) 2015-03-12
US8883771B2 (en) 2014-11-11
CN109575049A (zh) 2019-04-05
CA2882496C (en) 2020-07-14
RU2649975C2 (ru) 2018-04-06
KR20200054334A (ko) 2020-05-19
WO2014031487A1 (en) 2014-02-27
CA2882496A1 (en) 2014-02-27
WO2014031487A8 (en) 2014-05-30
JP6247298B2 (ja) 2017-12-13
KR102237888B1 (ko) 2021-04-07
EP2888265B1 (en) 2017-10-11
CN104718209A (zh) 2015-06-17
RU2015107552A (ru) 2016-10-10
CN109485662A (zh) 2019-03-19
HK1211030A1 (en) 2016-05-13
AU2013306087B2 (en) 2017-08-10
MX2015002371A (es) 2015-10-05
CN109485662B (zh) 2021-12-21
MX366130B (es) 2019-06-28
KR20150044937A (ko) 2015-04-27
EP2888265A4 (en) 2016-01-27
EP2888265A1 (en) 2015-07-01
US20140057924A1 (en) 2014-02-27
JP2015528447A (ja) 2015-09-28
KR102111704B1 (ko) 2020-05-15
CN109575049B (zh) 2021-07-30

Similar Documents

Publication Publication Date Title
ES3001186T3 (es) Ligandos peptídicos bicíclicos específicos para Nectina-4
Solárová et al. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies
US20130288980A1 (en) Targeting senescent and cancer cells for selective killing by interference with foxo4
AU2018335617B2 (en) Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer
Wu et al. Repurposing of niclosamide as a STAT3 inhibitor to enhance the anticancer effect of chemotherapeutic drugs in treating colorectal cancer
US20120130144A1 (en) Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor
KR20200078495A (ko) 암 치료를 위한 조성물 및 방법
CA3144985A1 (en) Hdac6-activated macrophages, compositions, and uses thereof
RU2682161C2 (ru) Противоопухолевое средство и усилитель противоопухолевого эффекта
JP2019511553A (ja) 静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ
Simioni et al. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells
WO2013152038A1 (en) Targeting senescent cells and cancer cells by interference with jnk and/or foxo4
TW200744636A (en) Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
Zhang et al. Silibinin-induced glioma cell apoptosis by PI3K-mediated but Akt-independent downregulation of FoxM1 expression
Liu et al. Inhibition of kinesin family member 20B sensitizes hepatocellular carcinoma cell to microtubule‐targeting agents by blocking cytokinesis
CN102137680A (zh) 用apoe肽治疗癌症的方法
CA2944255C (en) New derivatives of cephalosporin for treating cancer
CN115087463A (zh) 并用药物
Kim et al. Novel biological strategies to enhance the radiation therapeutic ratio
WO2024220891A1 (en) Compounds and uses thereof
Dong et al. The protective effect of new compound XH‐103 on radiation‐induced GI syndrome
KR20140056238A (ko) 약제의 병용에 의한 암 치료 방법
ES2353606T3 (es) Uso de la combinación que comprende temozolomida y tnf-alfa para el tratamiento del gioblastoma.
Huang et al. Molecular targeting of growth factor receptor signaling in radiation oncology
RU2693463C2 (ru) Противоопухолевое средство, содержащее таксановое соединение и усилитель противоопухолевого эффекта